{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:10:00Z","timestamp":1791339000937,"version":"4.3.1"},"reference-count":14,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T00:00:00Z","timestamp":1318809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Few effective therapeutic options exist for patients with refractory diffuse large B\u2010cell lymphoma (DLBCL). YM155 is a survivin suppressant with activity against DLBCL in a phase I trial. This phase II study was conducted to better characterize the toxicity and efficacy of this small molecule in patients with refractory DLBCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Forty\u2010one patients with a median age of 66 years and 3 prior regimens were enrolled and treated with a YM155 dose of 5 mg\/m<jats:sup>2<\/jats:sup>\/d by continuous infusion for 168 hours every 21 days for up to 15 cycles of treatment. The median number of completed cycles was 3.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>One patient had a complete remission (CR) (2.4%) with an additional 2 patients (5.9%) responding, with a median progression\u2010free survival of 58 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>YM155 was well tolerated with major toxicities including anemia and fatigue. Whereas YM155 had limited single\u2010agent activity, preclinical data suggest its role in combination with other agents, including rituximab, and a study of that combination in ongoing. Cancer 2012;118: 3128\u201334. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26510","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T12:24:13Z","timestamp":1318854253000},"page":"3128-3134","source":"Crossref","is-referenced-by-count":90,"title":["A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"118","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Lopez\u2010Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Seiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Shamsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/77929"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0897-917"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1768"},{"key":"e_1_2_6_7_2","first-page":"2462","article-title":"Regulation of microtubule stability and mitotic progression by survivin","volume":"62","author":"Giodini A","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1343"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1946"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2064"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9333-6"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1862"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.11.016"},{"issue":"15","key":"e_1_2_6_15_2","article-title":"Effect of YM155, a potent survivin suppressantm on the antitumor effect of rituximab in diffuse large B\u2010cell lymphomas (DLBCL) xenograft models: FLT\u2010\/FDG\u2010PET imaging studies","volume":"28","author":"Mitsuoka K","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:46:57Z","timestamp":1760280417000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,17]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6,15]]}},"alternative-id":["10.1002\/cncr.26510"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26510","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,17]]}}}